Ferster A, Azzi N, Bujan W, Devalck C, Fondu P, Nafa S, Toppet M, Sariban E
Unité d'Hémato-Oncologie, Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles.
Rev Med Brux. 1992 Jun;13(6):213-7.
Allogenic bone marrow transplantation (ABMT) is the only curative approach for sickle cell anemia and major beta-thalassemia. In sickle cell anemia, ABMT can be proposed for severe clinical disease. In major beta-thalassemia, it must be proposed to young patients who have an HLA identical familial donor.
异基因骨髓移植（ABMT）是镰状细胞贫血和重型β地中海贫血的唯一治愈方法。对于镰状细胞贫血，可对严重临床疾病患者考虑进行ABMT。对于重型β地中海贫血，必须对有人类白细胞抗原（HLA）相同的家族供者的年轻患者进行ABMT。
